Compare Enveric Biosciences Inc (ENVB) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs T Rowe Price Group Inc — how do they compare? Enveric Biosciences Inc trades at $1.36 (market cap $5.32M), while T Rowe Price Group Inc trades at $119.52 (market cap $25.41B). The key difference: T Rowe Price Group Inc is far larger — about 4776.3× Enveric Biosciences Inc's market cap, and T Rowe Price Group Inc pays a 4.39% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | TROW | |
|---|---|---|
Market Cap | $5.32M | $25.41B |
Sector | Health | Financials |
52-Week High | $17.40 | $120.16 |
52-Week Low | $1.28 | $86.19 |
Enterprise Value | $408.82K | $22.12B |
Dividend Yield | — | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
T. Rowe Price (TROW) trades at $116.07, up 2.13% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 12.72, net income margin of 28.28%, and consistent earnings beats. Recent AUM growth to $1.89 trillion and strategic institutional enhancements support positive momentum. Technical indicators show the stock trading near pivot point resistance at $116 with support at $115.
TROW presents a compelling value opportunity with attractive valuation metrics and strong profitability. The primary risk remains equity outflows despite diversification efforts. Analyst consensus is cautious with 63% hold ratings, though recent Zacks upgrades to Strong Buy highlight growing optimism. The stock's current price sits above the consensus target of $109.17, suggesting limited near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
